ArticleNPJ Parkinson's disease2022
Short-term effect of dopaminergic medication on speech in early-stage Parkinson's disease.
Article in NPJ Parkinson's disease, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 2 syntheses or guidelines pooled it, 32 citations in OpenAlex.
- Dopaminergic responsiveness and dopaminergic challenge tests of Parkinson's disease: a systematic review and meta-analysis.Journal of neurology · 2025Pooled it
- Quantifying articulatory impairments in neurodegenerative motor diseases: A scoping review and meta-analysis of interpretable acoustic features.International journal of speech-language pathology · 2023Pooled it
- "YiJinJing, Wohu Pushi" Posture-Voice Therapy for Dysarthria in Parkinson's Disease Patients Following Subthalamic Nucleus Deep Brain Stimulation: A Randomized Controlled Trial.CNS neuroscience & therapeutics · 2025Trial
- From phenotype to biology: a multi-modal roadmap of biofluid, tissue, imaging, and digital biomarkers in Parkinson's disease.Translational neurodegeneration · 2026Review
- Effects of STN-DBS treatment on voice characteristics in patients with Parkinson's Disease.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026Article
- Disorders of the Basal Ganglia and Cerebellum: A Comprehensive Review of Speech Sensorimotor Symptoms and Responses to Feedback Perturbations.Neurobiology of language (Cambridge, Mass.) · 2026Review
- When the body resonates with the pain of the other: Empathy Bodyssence in Parkinson's disease.Neuroscience of consciousness · 2026Article
- ParkMAE: a cross-linguistic masked autoencoder framework for robust Parkinson's disease detection from speech.Scientific reports · 2025Article
- Speech Markers of Parkinson's Disease: Phonological Features and Acoustic Measures.Brain sciences · 2025Article
- Digital speech biomarkers can measure acute effects of levodopa in Parkinson's disease.NPJ Parkinson's disease · 2025Article
- Automatic speech analysis combined with machine learning reliably predicts the motor state in people with Parkinson's disease.NPJ Parkinson's disease · 2025Article
- Parkinson's Disease, Speech and Neurosurgery.Brain and behavior · 2025Observational
- Spike-phase coupling of subthalamic neurons to posterior perisylvian cortex predicts speech sound accuracy.Nature communications · 2025Article
- Intra-individual Variations in Voice Variables Among Individuals With and Without Parkinson's Disease.Cureus · 2025Article
- Methylphenidate differentially affects the social ultrasonic vocalizations of wild-type and prodromal Parkinsonian rats.Behavioral neuroscience · 2025Article
- Effects of different side motor impairments at early onset on voice acoustic performance in patients with Parkinson's disease.Clinical parkinsonism & related disorders · 2025Article
- The spectrum of embodied intersubjective synchrony in empathy: from fully embodied to externally oriented engagement in Parkinson's disease.Frontiers in psychology · 2025Article
- Acoustic assessment in mandarin-speaking Parkinson's disease patients and disease progression monitoring and brain impairment within the speech subsystem.NPJ Parkinson's disease · 2024Review
- Subthalamic nucleus-language network connectivity predicts dopaminergic modulation of speech function in Parkinson's disease.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- A neurocomputational view of the effects of Parkinson's disease on speech production.Frontiers in human neuroscience · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
The effect of dopaminergic medication on speech has rarely been examined in early-stage Parkinson's disease (PD) and the respective literature is inconclusive and limited by inappropriate design with lack of PD control group. The study aims to examine the short-term effect of dopaminergic medication on speech in PD using patients with good motor responsiveness to levodopa challenge compared to a control group of PD patients with poor motor responsiveness. A total of 60 early-stage PD patients were investigated before (OFF) and after (ON) acute levodopa challenge and compared to 30 age-matched healthy controls. PD patients were categorised into two clinical subgroups (PD responders vs. PD nonresponders) according to the comparison of their motor performance based on movement disorder society-unified Parkinson's disease rating scale, part III. Seven distinctive parameters of hypokinetic dysarthria were examined using quantitative acoustic analysis. We observed increased monopitch (p > 0.01), aggravated monoloudness (p > 0.05) and longer duration of stop consonants (p > 0.05) in PD compared to healthy controls, confirming the presence of hypokinetic dysarthria in early PD. No speech alterations from OFF to ON state were revealed in any of the two PD groups and speech dimensions investigated including monopitch, monoloudness, imprecise consonants, harsh voice, slow sequential motion rates, articulation rate, or inappropriate silences, although a subgroup of PD responders manifested obvious improvement in motor function after levodopa intake (p > 0.001). Since the short-term usage of levodopa does not easily affect voice and speech performance in PD, speech assessment may provide a medication state-independent motor biomarker of PD.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.